Shearman & Sterling represented the underwriters in connection with the follow-on public offering by Protalix BioTherapeutics’ (Protalix) 8.75 million shares of common stock at a public offering price of $4.60 per share, resulting in aggregate gross proceeds to Protalix of approximately $40.2 million. The offering consisted of 8.75 million shares sold by Protalix, including 1,141,304 shares sold pursuant to the exercise in full of the option to purchase additional shares granted to the underwriters by Protalix in connection with the offering.
Bank of America Securities acted as the book-running manager and Oppenheimer & Co. acted as the co-manager for the offering.
Protalix is a biopharmaceutical company based in Israel focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell based expression system. In addition, Protalix’s development pipeline consists of other proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets.
The Shearman & Sterling team below also included associate Karen Mann.